A more recent study showed that the reprogrammed AR cistrome observed in mCRPC coincides with sites already bound by FOXA1 in normal and primary tumor tissue (15), further supporting a model where FOXA1 pre-marks a cancer-associated AR cistrome to facilitate prostate cancer progression (Figures 1B, C). This evidence concerns the gene FOXA1 and prostate cancer.